ClinicalTrials.gg
Drug

Visilizumab clinical trials

studies test it
13
open now
0
in phase 3
5
first study started
2001

How each study uses visilizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Visilizumab
12

Studies by the year they started

12 studies that test it; most in 2002 (3)

Studies that test visilizumab, by start year
YearStudies
20011
20023
20041
20052
20063
20071
20211

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
10
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 4

Facet Biotech (8) · Stanford University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Abbott (1) · The First Affiliated Hospital of Soochow University (1) · Fred Hutchinson Cancer Center (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses visilizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

Codes

What other systems call visilizumab · ClinicalTrials.gg INT004449

  • MeSH (NLM) C456519visilizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) H18SKU3289VISILIZUMABConfirmed FDA, NLM
  • NCI Thesaurus C2229VisilizumabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.